trending Market Intelligence /marketintelligence/en/news-insights/trending/CdfH6DLeLMuwYJLxjD4f_Q2 content esgSubNav
In This List

Former FDA commissioner joins Malin as chief medical adviser

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Former FDA commissioner joins Malin as chief medical adviser

Malin Corp. PLC appointed Andrew von Eschenbach to serve as chief medical adviser.

Von Eschenbach was previously an advisory partner to Malin. He served as the commissioner of the U.S. Food and Drug Administration from 2006 to 2009. Prior to that, he was the director of the National Cancer Institute at the National Institute of Health.

Von Eschenbach is the president of Samaritan Health Initiatives Inc.